QCM Cayman’s Alexion Pharmaceuticals ALXN Stock Holding History

QCM Cayman’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,123	Closed	-$264K	–	184
2018 Q2	$264K	Buy	+2,123	New	+$248K	1.22%	36
2016 Q1	–	Sell	-1,101	Closed	-$210K	–	258
2015 Q4	$210K	Buy	+1,101	New	+$192K	0.17%	100
2015 Q3	–	Sell	-2,524	Closed	-$456K	–	309
2015 Q2	$456K	Buy	+2,524	New	+$436K	0.17%	71
2014 Q4	–	Sell	-1,533	Closed	-$254K	–	312
2014 Q3	$254K	Buy	+1,533	New	+$252K	0.06%	143

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

QCM Cayman's ALXN Position: Q3 2018 in Review

QCM Cayman sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 2,123 shares — an estimated $264K sold.

QCM Cayman first reported a position in ALXN in Q3 2014 and held it in 4 quarters. The position peaked at $456K in Q2 2015. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

QCM Cayman reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
QCM Cayman sold 2,123 Alexion Pharmaceuticals shares in Q3 2018, an estimated $264K.
QCM Cayman first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 4 quarters.
QCM Cayman's Alexion Pharmaceuticals position peaked at $456K in Q2 2015.
584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on QCM Cayman's 13F filing for Q3 2018, filed 14 Nov 2018.